Omega-3 polyunsaturated fatty acids in depression: insights from recent clinical trials.
Level 1 - systematic review of randomized trials
Systematic review of randomized controlled trials
PubMed 39912390 · doi:10.1097/MCO.0000000000001077
What was done
Authors systematically searched PubMed, Cochrane, and Embase databases for randomized controlled trials published between May 2022 and May 2024 evaluating omega-3 polyunsaturated fatty acids in participants with clinically diagnosed depression. The review focused on major depressive disorder presentations involving high inflammation, comorbidities, and younger populations.
What was found
The abstract reports no numerical effect sizes, study counts, or participant totals. It reports qualitatively that higher doses of eicosapentaenoic acid (EPA >1 g/day) improved depression measures, particularly in patients with elevated inflammatory markers, comorbid cardiovascular disease, late-life onset, and in children and adolescents. Symptom improvements were associated with increases in anti-inflammatory and proresolving lipid mediators, as well as adjuvant benefits in cognitive, metabolic, and neurobiological measures.
Why it matters
This review highlights that therapeutic benefit from omega-3 supplementation may depend on higher EPA dosing and targeting inflammatory or specific clinical subtypes rather than unselected depression.
Limits
The abstract omits the number of included studies, total participant sample size, and quantitative effect sizes. Optimal dosing regimens, duration of treatment, long-term outcomes, and sex-specific differences remain uncharacterized.